(Q36299961)

13 August 2017

1 reference

title

Safety and adverse event profile of duloxetine (English)

1 reference

13 August 2017

Joachim F Wernicke

1

1 reference

13 August 2017

James Gahimer

2

1 reference

13 August 2017

Ilker Yalcin

3

1 reference

13 August 2017

Meghan Wulster-Radcliffe

4

1 reference

13 August 2017

Lars Viktrup

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Drug Safety

13 August 2017

1 reference

13 August 2017

4

1 reference

13 August 2017

6

1 reference

13 August 2017

987-993

1 reference

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine versus placebo in the treatment of stress urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine Treatment of Stress Urinary Incontinence in Women Does Not Induce Mania or Hypomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Cardiac disorders and antidepressant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.987

21 January 2018

Identifiers

DOI

10.1517/14740338.4.6.987

1 reference

13 August 2017

1 reference